

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
06 February 2020 (06.02.2020)



(10) International Publication Number
WO 2020/025703 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 35/00 (2006.01)
A61K 39/395 (2006.01) A61P 35/02 (2006.01)

(21) International Application Number:

PCT/EP2019/070693

(22) International Filing Date:

31 July 2019 (31.07.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

18306050.8 01 August 2018 (01.08.2018) EP
19153992.3 28 January 2019 (28.01.2019) EP

(71) Applicants: IMCHECK THERAPEUTICS SAS

[FR/FR]; 180 avenue du Prado, 13008 MARSEILLE (FR).
INSTITUT NATIONAL DE LA SANTE ET DE LA
RECHERCHE MEDICALE (INSERM) [FR/FR]; Etab-
lissement public national à caractère administratif, 101
rue de Tolbiac, 75013 PARIS (FR). UNIVERSITE AIX
MARSEILLE [FR/FR]; 53 boulevard Charles Livon,
13284 MARSEILLE CEDEX 07 (FR). INSTITUT JEAN
PAOLI & IRENE CALMETTE [FR/FR]; 232 boulevard
Sainte Marguerite, 13009 MARSEILLE (FR). CENTRE
NATIONAL DE LA RECHERCHE SCIENTIFIQUE
- CNRS - [FR/FR]; Etablissement Public, Scientifique et
Technologique (EPST), 3 rue Michel Ange, 75018 PARIS
(FR).

(72) Inventors: TRUNEH, Alemseged; 93 Atkinson Lane,

SUDBURY, Massachusetts 01776 (US). OLIVE, Daniel;
56 avenue Massenet, 13009 MARSEILLE (FR). PASERO,
Christine; 151 chemin de la Colline St Joseph, Bâ-
timent B, 13009 MARSEILLE (FR). DE GASSART,
Aude; c/o Imcheck Therapeutics, Campus du CNRS, 13009
MARSEILLE (FR).

(74) Agent: PLASSERAUD IP; 66 rue de la Chaussée d'Antin,
75440 PARIS CEDEX 09 (FR).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- with information concerning incorporation by reference of
missing parts and/or elements (Rule 20.6)

(54) Title: ANTI-BTN3A ANTIBODIES AND THEIR USE IN TREATING CANCER OR INFECTIOUS DISORDERS

(57) Abstract: The present invention relates to humanized antibodies that specifically bind to human BTN3A and their use in treating cancer and infectious disorders.

WO 2020/025703 A1